Abstract #2440

Treatment response assessment of malignant cancer cells to alpha-lipoic acid and a 213Bi-anti-EGFR-MAb with hyperpolarized [1-13C]-pyruvate

Benedikt Feuerecker¹, Christian Hundshammer¹, Christof Seidl², Alfred Morgenstern³, Frank Bruchertseifer³, Reingard Senekowitsch-Schmidtke¹, and Markus Schwaiger¹

¹Department of Nuclear Medicine, Technische Universität München, Munich, Germany, ²Department of Obstetrics and Gynaecology, Technische Universität München, Munich, Germany, ³European Commission Joint Research Centre Institute for Transuranium Elements, Karlsruhe, Germany

In the light of up regulation of glycolysis in tumors of the Warburg type, hyperpolarized ¹³C-labeled metabolic tracers offer new possibilities to probe fast metabolic pathways in real-time. As such, we assessed therapy response of malignant cancer cells to alpha-lipoic acid and a ²¹³Bi-anti-EGFR-MAb with hyperpolarized [1-¹³C]-pyruvate. Our results point to the fact that treatment of LN18 glioblastoma cells with LPA resulted in decreased proliferation/viability and reduced lactate export. Beyond, we demonstrated that NMR of hyperpolarized [1-¹³C]-pyruvate proved to be adequate for monitoring the response of bladder carcinoma cells to treatment with a ²¹³Bi-anti-EGFR-MAb as indicated by elevated pyruvate turnover.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.